ALK and small cell lung carcinoma: We report the fifth patient worldwide with SCLC harboring a fusion mutation in the EML4-ALK gene, who showed recurrent metastasis in the ipsilateral hilar lymph node at 18 months postoperatively and was diagnosed at 33 months postoperatively and was then started on treatment with the ALK-TKI ensartinib alone and achieved a PR efficacy with a PFS of more than 10 months and an OS of more than 43 months.